hat
Syantis yo gen tan vize pwoteyin beta-amyloid la, ki akimile nan sèvo yo nan pasyan alzayme a, men depi laj se yon sèl faktè nan pi gwo risk pou demans, yon dwòg ki vize li ta ka moso nan chèchè yo devinèt yo te kap chèche. J147 te kapab potansyèlman gen siksè nan lòt maladi neurodegenerative, tou, tankou Parkinson la. "Moun yo toujou panse ke ou bezwen dwòg separe pou alzayme a, Parkinson la ak konjesyon serebral," te di Schubert. "Men, li ka ke pa vize aje nou ka trete oswa ralanti anpil kondisyon patholojik ki gen laj ki asosye."
eng
Scientists have long targeted the protein beta-amyloid, which accumulates in the brains of Alzheimer’s patients, but since age is the single biggest risk factor for dementia, a drug that targets it could be the piece of the puzzle researchers have been looking for. J147 could potentially be successful in other neurodegenerative diseases, too, like Parkinson’s. “People have always thought that you need separate drugs for Alzheimer’s, Parkinson’s and stroke,” said Schubert. “But it may be that by targeting aging we can treat or slow down many pathological conditions that are old-age associated.”